Program
filgotinib
Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.
Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lakefront Biotherapeutics NVits history only | 230 open or running | phase 3since Sep 22, 2016 | Aug 10, 2010 | none ahead |
| Gilead Sciences | 160 open or running | phase 3since Aug 17, 2016 | Aug 17, 2016 | none ahead |
| Alfasigmaits history only | 74 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | Jun 2027phase 3 · NCT07554495 |
Also a collaborator on its studies: Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2016First studies: 3 phase 3 studies in Arthritis, RheumatoidFirst studyNCT02873936, NCT02886728, NCT02889796
- Sep 22, 2016Phase 3 study in Colitis, UlcerativeNCT02914522 · 1,351 enrolled · United States, Argentina, Australia and more
- Feb 6, 2017Phase 2 study in Small Bowel Crohn's DiseaseNCT03046056 · 78 enrolled · United States, Austria, Belgium and more
- Mar 8, 20172 phase 2 studiesNCT03077412, NCT03100942
- Apr 25, 2017Phase 2 study in Lupus Erythematosus, CutaneousNCT03134222 · 47 enrolled · United States, Canada
- Jun 30, 2017Phase 2 study in Noninfectious UveitisNCT03207815 · 74 enrolled · United States, Australia, Canada and more
- Sep 14, 2017Phase 2 study in Lupus Membranous NephropathyNCT03285711 · 9 enrolled · United States
- Jan 25, 2018Phase 1 study in Arthritis, RheumatoidNCT03417778 · 20 enrolled · United States, Germany, New Zealand
- Oct 2, 20192 phase 3 studies in Arthritis, PsoriaticNCT04115839, NCT04115748
- Jul 20, 20202 phase 3 studies in Spondylitis, AnkylosingNCT04483700, NCT04483687
- Oct 23, 2020Phase 1 study in Arthritis, RheumatoidNCT04608344 · 27 enrolled · United States
TargetBeta
“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 16 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04608344Arthritis, Rheumatoid · United States | 1 | Completed | Jan 13, 2021 | 27 |
| NCT04483700Spondylitis, Ankylosing | 3 | Withdrawn | Oct 2022 | 0 |
| NCT04483687Spondylitis, Ankylosing | 3 | Withdrawn | Jan 2023 | 0 |
| NCT04115839Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Terminated | Jan 4, 2021 | 106 |
| NCT04115748Arthritis, Psoriatic · United States, Australia, Bulgaria and more | 3 | Terminated | Jan 19, 2021 | 67 |
| NCT03417778Arthritis, Rheumatoid · United States, Germany, New Zealand | 1 | Completed | Aug 9, 2018 | 20 |
| NCT03285711Lupus Membranous Nephropathy · United States | 2 | Completed | May 3, 2019 | 9 |
| NCT03207815Noninfectious Uveitis · United States, Australia, Canada and more | 2 | Terminated | Dec 29, 2020 | 74 |
| NCT03134222Lupus Erythematosus, Cutaneous · United States, Canada | 2 | Completed | Mar 13, 2019 | 47 |
| NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more | 2 | Completed | Jan 10, 2019 | 152 |
| NCT03077412Fistulizing Crohn's Disease · United States, Austria, Belgium and more | 2 | Completed | Jan 20, 2021 | 57 |
| NCT03046056Small Bowel Crohn's Disease · United States, Austria, Belgium and more | 2 | Completed | Jul 20, 2020 | 78 |
| NCT02914522Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Mar 31, 2020 | 1,351 |
| NCT02889796Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Jul 4, 2018 | 1,759 |
| NCT02886728Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Oct 5, 2018 | 1,252 |
| NCT02873936Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Mar 20, 2018 | 449 |
How it is read
Names in the registry
- “Filgotinib”, 32 entries
- “GLPG0634”, 11 entries
- “filgotinib”, 3 entries
- “GLPG0634 50 mg”, 1 entry
- “GLPG0634 100 mg”, 1 entry
Codes read as this program: GLPG0634.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 12 studies
- Crohn Disease, 5 studies
- Colitis, Ulcerative, 4 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.